Venatorx Pharmaceuticals, a Malvern life sciences company, expects to hear from the Food and Drug Administration regarding its new drug application for its lead antibiotic candidate that has been over a decade in the making, writes John George for the Philadelphia Business Journal.
Cefepime-taniborbactam, the company’s potential flagship product, is an investigational combination antibiotic aimed at treating adults suffering from complicated urinary tract infections.
According to Future Market Insights, the global market for this ailment is estimated to be $11.2 billion and is expected to increase to $13.6 billion by 2034.
Since it was founded in 2010, Venatorx has managed to raise over $124 million from four rounds of equity financings and received an $8.9 million investment from the Wellcome Trust Translation Fund.
The company has also received several government contracts that support its work on finding new antibiotic treatments for multidrug-resistant bacterial infections as well as hard-to-treat viral infections.
In November, Venatorx and Melinta Therapeutics entered into an exclusive license agreement for the New Jersey company to commercialize cefepime-taniborbactam in the United States.
Read more about Venatorx Pharmaceuticals’ lead antibiotic candidate working to get approval in the Philadelphia Business Journal.
_____
